RESUMEN
We present a new approach for fabricating robust, regenerable antimicrobial coatings containing an ionic liquid (IL) phase incorporating silver nanoparticles (AgNPs) as a reservoir for Ag(0)/Ag(+) species within sol-gel-derived nanocomposite films integrating organosilicate nanoparticles. The IL serves as an ultralow volatility (vacuum-compatible) liquid target, allowing for the direct deposition and dispersion of a high-density AgNP "ionosol" following conventional sputtering techniques. Two like-anion ILs were investigated in this work: methyltrioctylammonium bis(trifluoromethylsulfonyl)imide, [N(8881)][Tf(2)N], and 1-ethyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide, [emim][Tf(2)N]. Silver ionosols derived from these two ILs were incorporated into silica-based sol-gel films and the resultant antimicrobial activity evaluated against Pseudomonas aeruginosa bacteria. Imaging of the surface morphologies of the as-prepared films established a link between an open macroporous film architecture and the observation of high activity. Nanocomposites based on [N(8881)][Tf(2)N] displayed excellent antimicrobial activity against P. aeruginosa over multiple cycles, reducing cell viability by 6 log units within 4 h of contact. Surprisingly, similar films prepared from [emim][Tf(2)N] presented negligible antimicrobial activity, an observation we attribute to the differing abilities of these IL cations to infiltrate the cell wall, regulating the influx of silver ions to the bacterium's interior.
Asunto(s)
Antibacterianos/química , Líquidos Iónicos/química , Nanopartículas del Metal/química , Nanocompuestos/química , Compuestos de Organosilicio/química , Plata/química , Antibacterianos/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Plata/farmacologíaRESUMEN
Research is currently underway worldwide into the development of receptor-specific radiopharmaceuticals for the imaging and treatment of cancer. The successful clinical development of radiolabeled somatostatin analogs for imaging and treatment of cancers overexpressing somatostatin receptors has catalyzed further preclinical investigation of other radiolabeled peptides for molecular imaging and peptide-receptor radiotherapy, including such well-studied peptide vectors as cholecystokinin, neurotensin, bombesin and RGD peptides. Within this larger context, this article will focus on the current status of two more recent additions to the list of molecular imaging targets - guanylate cyclase C, a specific marker for colorectal cancer, and the urokinase plasminogen activator receptor, a cell-surface receptor overexpressed in diverse cancer types.